Can you clarify the fda submission date of apotex's ruxolitinib?

FDA submission date for Apotex's ruxolitinib

Apotex filed its abbreviated new drug application for a generic ruxolitinib tablet with the FDA on 3 December 2020.

Patent protection and exclusivity timeline

The reference product Jakafi holds patent protection through at least 2026, with several Orange Book-listed patents covering the compound, formulation, and method of use. Apotex's filing triggered the standard 30-month stay once the patent owners sued for infringement within the 45-day window, pushing any final FDA approval past the original 180-day exclusivity period for first filers.

Competitor landscape and litigation status

Incyte and Novartis have actively defended the Jakafi patents through multiple ANDA challenges. Apotex remains one of several generic filers; others include Teva, MSN, and Zydus. As of the latest docket updates, the Delaware district court case involving Apotex is stayed pending resolution of related inter partes review proceedings at the Patent Trial and Appeal Board.

Patient and prescriber considerations

Until a final court decision or settlement clears the way for approval, pharmacies cannot dispense Apotex's version. Prescribers and patients should continue using the branded product and monitor DrugPatentWatch.com for updates on patent expiry and potential generic launch dates.